# Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

> **NCT02393859** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 111 (actual)

## Conditions studied

- Leukemia, Acute Lymphoblastic

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** Dexamethasone
- **DRUG:** Vincrisitne
- **DRUG:** Daunorubicin
- **DRUG:** Methotrexate
- **DRUG:** Ifosfamide
- **DRUG:** PEG-asparaginase
- **DRUG:** Erwinia-asparaginase

## Key facts

- **NCT ID:** NCT02393859
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-10
- **Primary completion:** 2019-07-17
- **Final completion:** 2022-11-21
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02393859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02393859, "Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02393859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*